Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022)
Lexicon Pharmaceuticals (LXRX) posted quarterly Non Operating Investment Income of -$27000.0 for Q1 2022, down 150.94% quarter-over-quarter from $53000.0 in Q2 2010.
Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Non Operating Investment Income for 2 consecutive years, with -$27000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Non Operating Investment Income changed N/A year-over-year to -$27000.0; the TTM figure through Mar 2022 stood at -$27000.0 (changed N/A YoY), while the FY2010 annual figure was $141000.0, down 87.98% from the prior year.
- Non Operating Investment Income eased to -$27000.0 in Q1 2022 per LXRX's latest filing, from $53000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at -$27000.0 in Q1 2022 and bottomed at -$27000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -27,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Jun 30, 2010 | 53,000.00 |
| Jun 30, 2010 | 53,000.00 |